Latest Conference Articles

December 14th 2021, 10:41pm

ASH Annual Meeting and Exposition

Cycle 1 double step-up dosing with cevostamab demonstrated encouraging activity with effective cytokine release syndrome mitigation in patients with heavily pretreated relapsed/refractory multiple myeloma, supporting further development of the dual-targeted bispecific antibody.

December 14th 2021, 9:34pm

ASH Annual Meeting and Exposition

Acalabrutinib demonstrated a lower incidence of cardiovascular-related toxicities and a lower overall toxicity burden compared with ibrutinib in patients with chronic lymphocytic leukemia.

December 14th 2021, 9:05pm

Pipeline Report: December 2021

The addition of tafasitamab and lenalidomide to rituximab, cyclophosphamide, doxorubicin, and prednisone demonstrated increased but generally comparable adverse effects and higher, prolonged, and deeper responses vs the combination of tafasitamab and R-CHOP alone in patients with previously untreated diffuse large B-cell lymphoma.

December 14th 2021, 8:54pm

ASH Annual Meeting and Exposition

Acalabrutinib demonstrated an advantage in quality-adjusted survival compared with other treatments for relapsed/refractory chronic lymphocytic leukemia.

December 14th 2021, 7:59pm

ASH Annual Meeting and Exposition

Magrolimab plus combinations of various antileukemia therapies are being investigated for their efficacy in first-line, relapsed/refractory, or maintenance treatment of acute myeloid leukemia.

December 14th 2021, 7:50pm

ASH Annual Meeting and Exposition

High-frequency low-dose acalabrutinib and rituximab represents a feasible and effective combination for the treatment of patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.

December 14th 2021, 6:56pm

ASH Annual Meeting and Exposition

Treatment with pacritinib, when administered at 200 mg twice daily, had a comparable safety profile to best available therapy in patients with cytopenic myelofibrosis, including those with severe thrombocytopenia.

December 14th 2021, 6:48pm

ASH Annual Meeting and Exposition

Sabatolimab, an investigational TIM-3 monoclonal antibody, induced a median duration of response greater than 1 year for patients with very high/high-risk myelodysplastic syndrome and acute myeloid leukemia when used in combination with hypomethylating agents.

December 14th 2021, 5:30pm

ASH Annual Meeting and Exposition

Patients with polycythemia vera who have controlled hematocrit levels, but elevated white blood counts are at an increased risk of thrombotic events, according to a presentation of the REVEAL study.

December 14th 2021, 5:05pm

ASH Annual Meeting and Exposition

YTB323, a novel, autologous CD19-directed CAR-T cell therapy, displayed a favorable safety profile and efficacy across multiple dose levels in adult patients with relapsed/refractory diffuse large b-cell lymphoma.

December 14th 2021, 4:52pm

ASH Annual Meeting and Exposition

Venetoclax at either 400 mg or 800 mg plus daratumumab and dexamethasone elicited deep durable responses and was associated with a tolerable safety profile in patients with t(11;14) relapsed/refractory multiple myeloma.

December 14th 2021, 4:09pm

ASH Annual Meeting and Exposition

Prognostic awareness was associated with higher rates of psychosocial distress and symptom burden, and lower quality of life in patients with multiple myeloma.

December 14th 2021, 3:43pm

ASH Annual Meeting and Exposition

Lower 60mg and 40mg doses of Selinexor in combination with bortezomib and dexamethasone demonstrated improved efficacy and safety vs a 100mg dose for patients with relapsed or refractory multiple myeloma.

December 14th 2021, 2:55pm

ASH Annual Meeting and Exposition

The combination of ibrutinib and venetoclax led to a lower rate of minimal residual disease compared with fludarabine, cyclophosphamide, and rituximab in patients with treatment-naïve chronic lymphocytic leukemia, according to preliminary findings from the phase 2 ERADIC trial.

December 14th 2021, 2:53pm

ASH Annual Meeting and Exposition

Frontline treatment with axicabtagene ciloleucel demonstrated rapid and durable responses in patients with high-risk large B-cell lymphoma.

December 14th 2021, 2:01pm

ASH Annual Meeting and Exposition

The addition of polatuzumab vedotin-piiq to R-CHP led to a 27% reduction in the risk of progression or death vs R-CHOP in patients with previously untreated, intermediate- and high-risk diffuse large B-cell lymphoma.

December 14th 2021, 2:01pm

ASH Annual Meeting and Exposition

As second-line treatment, tisagenlecleucel failed to demonstrate an event-free survival advantage compared with standard of care platinum-based chemotherapy followed by autologous stem cell transplant or additional chemotherapy in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.

December 13th 2021, 10:51pm

ASH Annual Meeting and Exposition

Noa Biran, MD, discusses the results of an arm of the ongoing phase 1b/2 STOMP trial evaluating selinexor, dosed at 40 or 60 mg, in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma.

December 13th 2021, 10:33pm

ASH Annual Meeting and Exposition

Paolo Ghia, MD, PhD, discusses the results from the minimal residual disease cohort of the phase 2 CAPTIVATE study in chronic lymphocytic leukemia that were presented during the 2021 ASH Annual Meeting & Exposition.

December 13th 2021, 9:53pm

ASH Annual Meeting and Exposition

The addition of ibrutinib to fludarabine, cyclophosphamide, and rituximab resulted in a higher rate of complete responses with bone marrow undetectable minimal residual disease in younger, fit patients with chronic lymphocytic leukemia.